Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors.

BACKGROUND De novo design of drug-like compounds with a desired pharmacological activity profile has become feasible through innovative computer algorithms. Fragment-based design and simulated chemical reactions allow for the rapid generation of candidate compounds as blueprints for organic synthesis. METHODS We used a combination of complementary virtual-screening tools for the analysis of de novo designed compounds that were generated with the aim to inhibit inactive polo-like kinase 1 (Plk1), a target for the development of cancer therapeutics. A homology model of the inactive state of Plk1 was constructed and the nucleotide binding pocket conformations in the DFG-in and DFG-out state were compared. The de novo-designed compounds were analyzed using pharmacophore matching, structure-activity landscape analysis, and automated ligand docking. One compound was synthesized and tested in vitro. RESULTS The majority of the designed compounds possess a generic architecture present in known kinase inhibitors. Predictions favor kinases as targets of these compounds but also suggest potential off-target effects. Several bioisosteric replacements were suggested, and de novo designed compounds were assessed by automated docking for potential binding preference toward the inactive (type II inhibitors) over the active conformation (type I inhibitors) of the kinase ATP binding site. One selected compound was successfully synthesized as suggested by the software. The de novo-designed compound exhibited inhibitory activity against inactive Plk1 in vitro, but did not show significant inhibition of active Plk1 and 38 other kinases tested. CONCLUSIONS Computer-based de novo design of screening candidates in combination with ligand- and receptor-based virtual screening generates motivated suggestions for focused library design in hit and lead discovery. Attractive, synthetically accessible compounds can be obtained together with predicted on- and off-target profiles and desired activities.

[1]  Michael M. Hann,et al.  RECAP-Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry , 1998, J. Chem. Inf. Comput. Sci..

[2]  A. Cheng,et al.  Structure of the catalytic domain of human polo-like kinase 1. , 2007, Biochemistry.

[3]  J. Hiltunen,et al.  Crystal structure of the liganded SCP-2-like domain of human peroxisomal multifunctional enzyme type 2 at 1.75 A resolution. , 2001, Journal of molecular biology.

[4]  C. Supuran,et al.  The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms. , 2009, Bioorganic & medicinal chemistry letters.

[5]  S. Loibl,et al.  Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells , 2002, Oncogene.

[6]  W. Guida,et al.  The art and practice of structure‐based drug design: A molecular modeling perspective , 1996, Medicinal research reviews.

[7]  J Gasteiger,et al.  Checking the projection display of multivariate data with colored graphs. , 1997, Journal of molecular graphics & modelling.

[8]  R. Abagyan,et al.  Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states. , 2008, Journal of medicinal chemistry.

[9]  L. Pearl,et al.  Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. , 1999, Journal of medicinal chemistry.

[10]  K. Strebhardt,et al.  Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy , 2010, Nature Reviews Drug Discovery.

[11]  Marcel L Verdonk,et al.  General and targeted statistical potentials for protein–ligand interactions , 2005, Proteins.

[12]  Jan M. Kriegl,et al.  Self-organizing fuzzy graphs for structure-based comparison of protein pockets. , 2010, Journal of proteome research.

[13]  R. Glen,et al.  Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. , 1995, Journal of molecular biology.

[14]  G. Klebe.  Virtual ligand screening: strategies, perspectives and limitations , 2006, Drug Discovery Today.

[15]  J. Mestan,et al.  Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. , 2004, Biochimica et biophysica acta.

[16]  Renxiao Wang,et al.  The PDBbind database: methodologies and updates. , 2005, Journal of medicinal chemistry.

[17]  P Schneider,et al.  Self-organizing maps in drug discovery: compound library design, scaffold-hopping, repurposing. , 2009, Current medicinal chemistry.

[18]  Matthias Rarey,et al.  Similarity searching in large combinatorial chemistry spaces , 2001, J. Comput. Aided Mol. Des..

[19]  Gisbert Schneider,et al.  Collection of bioactive reference compounds for focused library design , 2003 .

[20]  Dimitris K. Agrafiotis,et al.  Stochastic Algorithms for Maximizing Molecular Diversity , 1997, J. Chem. Inf. Comput. Sci..

[21]  Gisbert Schneider,et al.  Kernel Approach to Molecular Similarity Based on Iterative Graph Similarity , 2007, J. Chem. Inf. Model..

[22]  Klaus-Robert Müller,et al.  From Machine Learning to Natural Product Derivatives that Selectively Activate Transcription Factor PPARγ , 2010, ChemMedChem.

[23]  Stephen Davey.  Chemistry: Thinking outside the flask , 2009, Nature.

[24]  S. J. Campbell,et al.  Visualizing the drug target landscape. , 2010, Drug discovery today.

[25]  Irini Akritopoulou-Zanze,et al.  Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors. , 2009, Drug discovery today.

[26]  Schmid,et al.  "Scaffold-Hopping" by Topological Pharmacophore Search: A Contribution to Virtual Screening. , 1999, Angewandte Chemie.

[27]  D. Fabbro,et al.  Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors. , 2004, Current opinion in drug discovery & development.

[28]  Pu Liu,et al.  Stochastic Proximity Embedding: Methods and Applications , 2010, Molecular informatics.

[29]  J. Peters,et al.  The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1 , 2007, Current Biology.

[30]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[31]  P. Seeburg,et al.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.

[32]  Gisbert Schneider,et al.  The concept of template-based de novo design from drug-derived molecular fragments and its application to TAR RNA , 2008, J. Comput. Aided Mol. Des..

[33]  L. Tong,et al.  Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site , 2002, Nature Structural Biology.

[34]  Eyke Hüllermeier,et al.  Functional Classification of Protein Kinase Binding Sites Using Cavbase , 2007, ChemMedChem.

[35]  Peter Ertl,et al.  Bioisosteric Replacement and Scaffold Hopping in Lead Generation and Optimization , 2010, Molecular informatics.

[36]  José L. Medina-Franco,et al.  Characterization of Activity Landscapes Using 2D and 3D Similarity Methods: Consensus Activity Cliffs , 2009, J. Chem. Inf. Model..

[37]  Roderick E Hubbard,et al.  Informatics and modeling challenges in fragment-based drug discovery. , 2007, Current opinion in drug discovery & development.

[38]  John G Cumming,et al.  Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase. , 2004, Bioorganic & medicinal chemistry letters.

[39]  William L Jorgensen,et al.  Efficient drug lead discovery and optimization. , 2009, Accounts of chemical research.

[40]  Jean-Louis Reymond,et al.  Virtual exploration of the small-molecule chemical universe below 160 Daltons. , 2005, Angewandte Chemie.

[41]  Petra Schneider,et al.  De novo design of molecular architectures by evolutionary assembly of drug-derived building blocks , 2000, J. Comput. Aided Mol. Des..

[42]  G. Klebe,et al.  A new method to detect related function among proteins independent of sequence and fold homology. , 2002, Journal of molecular biology.

[43]  G. Schneider,et al.  PocketPicker: analysis of ligand binding-sites with shape descriptors , 2007, Chemistry Central Journal.

[44]  R. Marmorstein,et al.  Structural basis for nicotinamide cleavage and ADP-ribose transfer by NAD(+)-dependent Sir2 histone/protein deacetylases. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[45]  G. Schneider,et al.  Identification and Validation of a Potent Type II Inhibitor of Inactive Polo‐like Kinase 1 , 2009, ChemMedChem.

[46]  Vasso Apostolopoulos,et al.  Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: a new approach for vaccine design. , 2002, Journal of molecular biology.

[47]  Anna Vulpetti,et al.  Predicting Polypharmacology by Binding Site Similarity: From Kinases to the Protein Universe , 2010, J. Chem. Inf. Model..

[48]  Kirsch,et al.  Virtual Screening for Bioactive Molecules by Evolutionary De Novo Design Special thanks to Neil R. Taylor for his help in preparation of the manuscript. , 2000, Angewandte Chemie.

[49]  H. Simmonite,et al.  Nucleoside analogues as highly potent and selective inhibitors of herpes simplex virus thymidine kinase. , 2001, Bioorganic & medicinal chemistry letters.

[50]  Jordi Mestres,et al.  Computational chemogenomics approaches to systematic knowledge-based drug discovery. , 2004, Current opinion in drug discovery & development.

[51]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.

[52]  Lin Hong,et al.  Design, Synthesis and X-ray Structure of Protein−Ligand Complexes: Important Insight into Selectivity of Memapsin 2 (β-Secretase) Inhibitors , 2006 .

[53]  J. Bajorath,et al.  Activity landscape representations for structure-activity relationship analysis. , 2010, Journal of medicinal chemistry.

[54]  Ben M. Webb,et al.  Comparative Protein Structure Modeling Using MODELLER , 2007, Current protocols in protein science.

[55]  Hiroshi Yamashita,et al.  A Quantitative Approach to the Estimation of Chemical Space from a Given Geometry by the Combination of Atomic Species , 2007 .

[56]  Péter Lénárt,et al.  BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo , 2007, Current Biology.

[57]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[58]  Gisbert Schneider,et al.  Virtual screening: an endless staircase? , 2010, Nature Reviews Drug Discovery.

[59]  Wolfgang Guba,et al.  Recent developments in de novo design and scaffold hopping. , 2008, Current opinion in drug discovery & development.

[60]  Markus Hartenfeller,et al.  De novo drug design. , 2010, Methods in molecular biology.

[61]  Richard M. Jackson,et al.  Binding Site Similarity Analysis for the Functional Classification of the Protein Kinase Family , 2009, J. Chem. Inf. Model..

[62]  G. Schneider,et al.  Biological impact of freezing Plk1 in its inactive conformation in cancer cells , 2010, Cell cycle.

[63]  Petra Schneider,et al.  Self-organizing molecular fingerprints: a ligand-based view on drug-like chemical space and off-target prediction. , 2009, Future medicinal chemistry.

[64]  Tudor I. Oprea,et al.  Chemography: the Art of Navigating in Chemical Space , 2000 .

[65]  I K Fodor,et al.  A Survey of Dimension Reduction Techniques , 2002 .

[66]  G. Schneider,et al.  Voyages to the (un)known: adaptive design of bioactive compounds. , 2009, Trends in biotechnology.

[67]  D. Heerding,et al.  Chapter 23 Small Molecule Inhibitors of AKT/PKB Kinase as a Strategy for Treating Cancer , 2007 .

[68]  J. Breed,et al.  SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[69]  Gisbert Schneider,et al.  Computer-based de novo design of drug-like molecules , 2005, Nature Reviews Drug Discovery.